OakChart

Acurx Pharmaceuticals Inc

ACXPHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 11:44 AM ET

1.05+0.01 (1.44%)
2026-11-11 17:45 CET
Market cap
5.78 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-7.51 USD m
Free cash flow, TTM
-6.18 USD m
EPS diluted, TTM
-3.05
P/E
-
Compare

Price

ACXP against its 20, 50 and 200-day averages
2050200beatmissearnings
1.002.003.004.00552K1.1MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ACXPclose 1.0620-day 1.0850-day 1.23200-day 1.911.06

86.0% under the 52-week high of 7.54 on 19 Mar 2026. 52-week low 0.95 on 5 Nov 2026. Last 15 sessions, 25.3% high to low

Profile

ACXP
52-week range, 2% of the way up
0.957.54

Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.

Employees4
IPOJun 25, 2021
Beta-2.08
ATR, 14d0.07
Rel volume0.47
Short float1.91%
Insider own8.12%
Inst own2.66%

Snapshot

6 groups

Valuation

Index-
Market Cap5.86M
Enterprise Value-4.80M
Income-7.51M
Sales0.00M
Book/sh1.74
Cash/sh1.92
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees4
IPOJun 25, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.61
P/C0.55
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio3.88
Current Ratio3.88
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-3.05
EPS next Y-1.50
EPS next Q-0.38
EPS this Y67.67%
EPS next Y12.79%
EPS next 5Y31.04%
EPS past 3/5Y38.05% 10.54%
Sales past 3/5Y- -
EPS Y/Y TTM71.66%
Sales Y/Y TTM-
EPS Q/Q71.96%
Sales Q/Q-
EarningsNov 12 BMO
EPS/Sales Surpr.-40.70% -

Ownership

Insider Own8.12%
Insider Trans0.00%
Inst Own2.66%
Inst Trans4.91%
ROA-87.57%
ROE-128.11%
ROIC-92.08%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-2.23%
SMA50-14.45%
SMA200-44.78%
Trades-

Technical

Shs Outstand5.56M
Shs Float5.11M
Short Float1.91%
Short Ratio0.78
Short Interest0.10M
52W High7.54 -86.01%
52W Low0.95 11.56%
Volatility8.61% 6.42%
ATR (14)0.07
RSI (14)41.91
Beta-2.08
Rel Volume0.47
Avg Volume124.80K
Volume21,864

Performance

Perf Week2.43%
Perf Month-12.08%
Perf Quarter-28.72%
Perf Half Y-46.98%
Perf YTD-57.63%
Perf Year-81.09%
Perf 3Y-98.63%
Perf 5Y-98.94%
Perf 10Y-
Recom1.00
Target Price17.00
Prev Close1.04
Price1.05
Change %1.44%

Peers

Mkt cap
TickerCompanyMkt cap
MCRBSeres Therapeutics Inc14.27M
TOVXTheriva Biologics Inc7.29M
SPROSpero Therapeutics Inc59.69M
ARMPArmata Pharmaceuticals Inc135.15M
CRMDCorMedix Inc413.49M
SNGXSoligenix Inc7.56M
PYPDPolypid Ltd137.11M
SXTP60 Degrees Pharmaceuticals Inc1.83M
IMRNImmuron Limited ADR7.48M
COCPCocrystal Pharma Inc19.83M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 204
  • Acurx Heads Into Q3 With Pathfinder Funded But Its Phase 3 Partner Still Missing (Earnings Whispers) +12.09%
  • Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update (PR Newswire)
  • Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect (PR Newswire)
  • Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection (PR Newswire)
  • Loading…
  • Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ... (GuruFocus.com)
  • Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat (PR Newswire) +18.28%
  • Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update (PR Newswire) -5.74%
  • Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics (PR Newswire)
  • Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics (PR Newswire)
  • FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection (PR Newswire)
  • Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection (PR Newswire)
  • Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update (PR Newswire) -6.21%
  • Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--0.377--0.003
2026Q22026-08-14-0.530-0.377-0.5300.000.003
2026Q12026-05-12-0.620-1.200-0.6180.000.003
2025Q42026-03-13-0.730-1.013-0.6720.000.003
2025Q32025-11-12-1.230-1.310-1.2260.000.003
2025Q22025-08-12-1.890-2.333-1.8870.000.003
2025Q12025-05-13-2.200-2.600-2.1450.00-3
2024Q42025-03-18-3.200-3.500-3.267--2
2024Q32024-11-13-3.400-2.900-3.449--2
2024Q22024-08-09-5.200-3.300-5.209--2
2024Q12024-05-15-5.600-3.000-5.659--1
2023Q42024-03-18-7.400-4.900-7.599--2
2023Q32023-11-14-4.800-5.400-4.790--3
2023Q22023-08-14-5.600-4.666-5.654--3
2023Q12023-05-12-5.000-4.700-4.9880.000.002
2022Q42023-03-16-5.600-5.800-5.6190.000.003

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-29.800--24.957--
2022FY-22.400-22.466-22.360--
2023FY-23.000-20.300-23.009--
2024FY-17.400-16.800-17.451--
2025FY-5.320-6.047-5.3200.000.00
2026FY--1.720--0.00
2027FY--1.500--0.00
2028FY--1.745---
2029FY--1.710---
2030FY-0.760--55.71

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-141000.000.000.00
2026Q3S2026-05-121000.000.000.00
2026Q3S2026-03-131000.000.000.00
2026Q3R2026-10-31100-0.28-0.28-0.28
2026Q3R2026-08-17101-0.28-0.28-0.28
2026Q3R2026-08-14100-0.19-0.19-0.19
2026Q3R2026-07-26100-0.19-0.19-0.19
2026Q3R2026-05-12110-0.19-0.19-0.19
2026Q3R2026-03-13110-0.45-0.45-0.45
2026Q3R2026-03-04110-0.45-0.45-0.45
2026Q3R2026-01-26100-0.76-0.76-0.76
2026Q3R2025-11-12101-0.76-0.76-0.76
2026Q3R2025-11-11100-0.75-0.75-0.75
2026Q3R2025-11-10100-0.75-0.75-0.75

Estimate history

EPS, annual-11.963-9.278-24.957-22.36-23.009-17.451-5.315-3.0454
Period2019202020212022202320242025TTM
EPS, quarterly-5.209-3.449-3.267-2.145-1.887-1.226-0.672-0.618-0.529
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00000000
Period2019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.4960.4960.5110.5810.7230.8522.3484.683
Period2019202020212022202320242025MRQ
Shares, quarterly0.80.8390.8521.121.471.82.3483.3894.683
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other7.678.0914.1014.5812.0912.814.605.93
Research and Development2.121.835.406.044.752.032.203.51
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-7.67-8.09-14.10-14.58-12.09-12.81-4.60-5.93
Interest Expense0.000.000.000.000.000.00-0.00
Unusual Expense-0.000.000.000.00-0.070.000.00
Net Income Before Taxes-7.51-7.97-14.10-14.58-12.09-12.75-4.60-5.93
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-7.51-7.97-14.10-14.58-12.09-12.75-4.60-5.93
Net Income From Continuing Operations-7.51-7.97-14.10-14.58-12.09-12.75-4.60-5.93
Net Income-7.51-7.97-14.10-14.58-12.09-12.75-4.60-5.93
EPS (Recurring)-1.76-5.32-17.45-23.01-22.36-25.05-9.28-11.96
EPS (Basic, Before Extraordinaries)-3.05-5.32-17.45-23.01-22.36-24.96-9.28-11.96
EPS (Diluted)-3.05-5.32-17.45-23.01-22.36-24.96-9.28-11.96
EBITDA-7.67-8.09-14.10-14.58-12.09-12.81-4.60-5.93
Non-Operating Income (Expense)0.160.130.000.000.000.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.051.252.603.212.870.760.700.57
Shares Outstanding4.682.350.850.720.580.510.500.50
Market Capitalization5.785.7813.8649.8146.1444.1544.56-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other2.311.721.622.032.272.152.782.82
Research and Development1.070.340.280.430.520.600.831.20
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.31-1.72-1.62-2.03-2.27-2.15-2.78-2.82
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.00-0.000.000.000.00
Net Income Before Taxes-2.25-1.68-1.58-1.99-2.25-2.15-2.78-2.82
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-2.25-1.68-1.58-1.99-2.25-2.15-2.78-2.82
Net Income From Continuing Operations-2.25-1.68-1.58-1.99-2.25-2.15-2.78-2.82
Net Income-2.25-1.68-1.58-1.99-2.25-2.15-2.78-2.82
EPS (Recurring)-0.53-0.62-0.67-1.23-1.89-2.15-3.27-3.45
EPS (Basic, Before Extraordinaries)-0.53-0.62-0.67-1.23-1.89-2.15-3.27-3.45
EPS (Diluted)-0.53-0.62-0.67-1.23-1.89-2.15-3.27-3.45
EBITDA-2.31-1.72-1.62-2.03-2.27-2.15-2.78-2.82
Non-Operating Income (Expense)0.050.040.040.040.020.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.200.260.290.290.321.000.351.04
Shares Outstanding4.683.392.351.801.471.120.850.84
Market Capitalization5.7810.595.196.8015.028.7313.8631.86

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments7.563.717.479.1112.963.182.48
Short Term Receivables0.050.050.130.000.000.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets0.090.100.110.260.300.050.05
Total Current Assets7.693.867.719.3813.253.222.53
Net Property, Plant & Equipment0.000.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.000.00
Total Assets7.693.867.719.3813.253.222.53
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.020.00
Accounts Payable0.000.000.000.000.000.000.00
Other Current Liabilities2.423.243.042.060.840.461.71
Total Current Liabilities2.423.243.042.060.840.471.71
Long Term Debt0.000.000.000.000.000.050.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.00
Total Liabilities2.423.243.042.060.840.521.71
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity5.270.624.677.3212.412.700.82
Total Shareholders Equity5.270.624.677.3212.412.700.82
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity5.270.624.677.3212.412.700.82
Total Liabilities & Stockholders Equity7.693.867.719.3813.253.222.53
Book Value Per Share2.240.726.4512.5824.305.451.65
Tangible Book Value Per Share2.240.726.4512.5824.305.451.65
Full-Time Employees44443--
Price to Book Ratio0.6022.5412.664.733.563.12-
Return on Assets-137.98-243.85-170.64-106.87-154.72-159.85-
Return on Equity-270.80-534.03-243.33-122.61-168.71-261.26-
Return on Invested Capital-151.21-2,292.74-312.38-165.31-102.72-167.19-723.45
Quick Ratio3.181.192.534.5515.716.821.48
Current Ratio3.181.192.534.5515.716.821.48

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-7.51-7.97-14.10-14.58-12.09-12.75-4.60-5.93
Other Funds (Non Cash)1.321.573.443.773.307.592.050.90
Funds from Operations-6.19-6.40-10.67-10.81-8.79-5.15-2.55-5.03
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital0.01-0.390.281.011.250.14-0.801.05
Cash from Operating Activities-6.18-6.79-10.38-9.80-7.54-5.01-3.35-3.99
Capital Expenditures0.000.000.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock10.7810.646.415.943.7014.803.984.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock10.7810.646.415.943.7014.803.984.00
Proceedsfrom Stock Options9.426.806.415.943.7014.803.984.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.070.00
Change in Long Term Debt0.000.000.000.000.000.000.070.00
Issuance of Long Term Debt0.000.000.000.000.000.000.070.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.00-0.000.212.220.000.000.000.45
Other Financing Activities Uses-0.00-0.000.000.000.000.000.00-
Cash from Financing Activities10.7810.646.628.163.7014.804.044.46
Net Change in Cash4.593.85-3.77-1.64-3.859.780.690.47
Free Cash Flow-6.18-6.79-10.38-9.80-7.54-5.01-3.35-3.99
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments10.669.257.565.916.064.64
Short Term Receivables0.100.060.050.040.040.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.230.230.090.160.050.16
Total Current Assets10.989.547.696.116.164.81
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets10.989.547.696.116.164.81
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable0.000.000.000.000.000.00
Other Current Liabilities2.832.532.422.472.592.49
Total Current Liabilities2.832.532.422.472.592.49
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities2.832.532.422.472.592.49
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity8.157.015.273.643.572.31
Total Shareholders Equity8.157.015.273.643.572.31
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity8.157.015.273.643.572.31
Total Liabilities & Stockholders Equity10.989.547.696.116.164.81
Book Value Per Share1.742.072.242.022.432.06
Tangible Book Value Per Share1.742.072.242.022.432.06
Full-Time Employees--4---
Price to Book Ratio0.601.651.231.774.213.78
Return on Assets-87.57-104.54-137.98-151.72-156.99-170.68
Return on Equity-128.11-160.83-270.80-291.07-285.93-285.79
Return on Invested Capital-27.65-23.97-29.96-54.79-62.99-92.98
Quick Ratio3.883.783.182.472.381.93
Current Ratio3.883.783.182.472.381.93

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-2.25-1.68-1.58-1.99-2.25-2.15
Other Funds (Non Cash)0.280.320.380.340.410.44
Funds from Operations-1.97-1.36-1.20-1.65-1.84-1.71
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.26-0.050.02-0.230.17-0.35
Cash from Operating Activities-1.71-1.41-1.18-1.88-1.67-2.05
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock3.113.112.831.723.092.99
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.113.112.831.723.092.99
Proceedsfrom Stock Options3.113.111.471.720.612.99
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-0.000.000.00
Other Financing Activities Uses0.000.000.00-0.000.000.00
Cash from Financing Activities3.113.112.831.723.092.99
Net Change in Cash1.401.701.65-0.161.420.94
Free Cash Flow-1.71-1.41-1.18-1.88-1.67-2.05

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.91%0.1M5.1M118.89K
2026-10-151.78%0.1M5.1M121.48K
2026-09-302.19%0.1M5.1M128.06K
2026-09-152.43%0.1M5.1M123.41K
2026-08-312.40%0.1M5.0M124.15K
2026-08-141.94%0.1M4.8M103.73K
2026-07-313.24%0.1M4.0M93.99K
2026-07-152.59%0.1M4.0M116.04K
2026-06-303.43%0.1M4.0M123.45K
2026-06-152.74%0.1M4.0M535.69K
2026-05-292.28%0.1M4.0M3.10M
2026-05-153.62%0.1M4.0M3.09M
2026-04-303.41%0.1M3.4M3.13M
2026-04-152.81%0.1M3.4M3.15M
2026-03-313.90%0.1M2.6M3.14M
2026-03-1339.92%1.0M2.6M2.70M
2026-02-272.47%0.1M2.3M61.75K
2026-02-133.15%0.1M2.3M58.82K
2026-01-303.03%0.1M2.3M65.89K
2026-01-153.69%0.1M2.2M74.92K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-298-KCurrent report2026-10-29SEC
2026-10-168-KCurrent report2026-10-16SEC
2026-09-17EFFECTEffectiveness filing by commission orderSEC
2026-09-17424B3SEC
2026-09-08S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-09-01ARSAnnual report to security holders. 2025-12-31SEC
2026-09-01DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-01DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-16SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-05-12424B3SEC
2026-05-12424B3SEC
2026-05-11EFFECTEffectiveness filing by commission orderSEC
2026-05-11EFFECTEffectiveness filing by commission orderSEC
2026-05-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-07CORRESPSEC
2026-05-07CORRESPSEC
2026-05-07UPLOADUpload SubmissionSEC
2026-05-07UPLOADUpload SubmissionSEC
2026-05-04S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-05-04S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-04-29DNotice of sales of securities on Form D (Regulation D)SEC
2026-04-224Statement of changes in beneficial ownership of securities2026-04-20SEC
2026-04-224Statement of changes in beneficial ownership of securities2026-04-20SEC
2026-04-224Statement of changes in beneficial ownership of securities2026-04-20SEC
2026-04-224Statement of changes in beneficial ownership of securities2026-04-20SEC
2026-04-224Statement of changes in beneficial ownership of securities2026-04-20SEC
2026-04-224Statement of changes in beneficial ownership of securities2026-04-20SEC
2026-04-224Statement of changes in beneficial ownership of securities2026-04-20SEC
2026-04-224Statement of changes in beneficial ownership of securities2026-04-20SEC
2026-04-168-KCurrent report2026-04-15SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC0.72%
GEODE CAPITAL MANAGEMENT, LLC0.47%
VANGUARD FIDUCIARY TRUST CO0.38%
JANE STREET GROUP, LLC0.37%
Prospect Financial Services LLC0.32%
LANARK FINANCIAL, INC.0.27%
Cambridge Investment Research Advisors, Inc.0.27%
MORGAN STANLEY0.17%
Tower Research Capital LLC0.06%
WELLS FARGO & COMPANY/MN0.05%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.72%
Fidelity Extended Market Index Fund0.40%
Fidelity Series Total Market Index Fund0.06%
Fidelity Total Market Index Fund0.02%
Fidelity Nasdaq Composite Index Fund0.00%

OakChart. ACXP. Cached 15 minutes.

Some panels did not load: ratings, insider.